Table 2.
The list of clinical trials of CQ against COVID-19 in China.
| Number | Registration number | Registration name | Type of clinical trial | Registration date | Group | Progress | Anticipated execute time | |
|---|---|---|---|---|---|---|---|---|
| Intervention | Comparator | |||||||
| 1 | ChiCTR2000029609 | A prospective, open, multicenter clinical study on the treatment of COVID-19 with chloroquine phosphate | Intervention study | 6/2/2020 | Mild-moderate chloroquine group: chloroquine phosphate was taken by oral Mild-moderate combination group: chloroquine phosphate plus Lopinavir/ritonavir was taken by oral Severe-chloroquine group: chloroquine phosphate was taken by oral |
Mild-moderate group Lopinavir/ritonavir group: oral Lopinavir/ritonavir Severe-group Lopinavir/ritonavir group: oral Lopinavir/ritonavir |
Not yet recruiting. | From 2020-02-10 To 2020-12-31. The time of sharing IPD will be within 6 months after the trial complete. |
| 2 | ChiCTR2000029826 | A randomized, double-blind, parallel-controlled study of chloroquine phosphate combined with standard therapy versus standard therapy for severe/critical COVID-19 | Intervention study | 14/2/2020 | Phosphoric chloroquine: two tablets phosphoric chloroquine bid | Placebo two tablets placebo bid | Canceled by the investigator | From 2020-02-17 To 2020-03-17 |
| 3 | ChiCTR2000029837 | A randomized, double-blind, parallel-controlled study of chloroquine phosphate combined with standard therapy versus standard therapy for mild/normal COVID-19 | Intervention study | 15/2/2020 | Phosphoric chloroquine: two tablets phosphoric chloroquine bid | Placebo two tablets placebo bid | Canceled by the investigator | From 2020-02-17 To 2020-03-17 |
| 4 | ChiCTR2000029935 | Single-arm clinical study on the treatment of COVID-19 with chloroquine phosphate | Intervention study | 16/2/2020 | Treated with conventional treatment combined with chloroquine phosphate | Conventional therapy | Recruiting | From 2020-02-06 To 2021-02-06 The time of sharing IPD will be within 6 months after the trial complete. |
| 5 | ChiCTR2000029939 | A single blind, randomized, controlled clinical trial of chloroquine phosphate tablets in the treatment of COVID-19 | Intervention study | 16/2/2020 | Conventional treatment with chloroquine phosphate | The conventional treatment group will be treated according to the guidance of the “Diagnosis and Treatment Scheme of COVID-19” published by the National Health Commission | Recruiting | From 2020-02-06 To 2021-02-06 The time of sharing IPD will be within 6 months after the trial complete. |
| 6 | ChiCTR2000029975 | Single-arm clinical study on the treatment of COVID-19 with chloroquine phosphate | Intervention study | 18/2/2020 | In addition to the routine treatment, add 150 mg chloroquine phosphate dissolved in 5 ml of normal saline, q12h, inhaled by atomization for 1 week. | Conventional therapy | Not yet recruiting. | From 2020-02-24 To 2020-05-31 The time of sharing IPD Within 6 months after the trial complete |
| 7 | ChiCTR2000029988 | Chloroquine phosphate treatment for severe COVID-19 | Intervention study | 18/2/2020 | Chloroquine Phosphate | Conventional therapy | Recruiting | From 2020-02-13 To 2020-05-31 The time of sharing IPD will be within 6 months after the trial complete. |
| 8 | ChiCTR2000029992 | A prospective, open randomized controlled trial of chloroquine phosphate and hydroxychloroquine sulfate in patients with COVID-19 | Intervention study | 18/2/2020 | Hydroxychloroquine sulfate gloup: Hydroxychloroquine sulfate 0.2 g bid for 14 days Chloroquine phosphate gloup: The first dose of chloroquine phosphate was 1 g for 2 days, and the 3rd day was 0.5 g for 12 days |
Recommended treatment plan for novel coronavirus pneumonia severe and critical cases | Not yet recruiting. | From 2020-02-17 To 2020-05-20 The time of sharing IPD will be within 6 months after the trial complete. |
| 9 | ChiCTR2000030031 | A randomized, double-blind, parallel-controlled study of chloroquine phosphate combined with standard therapy versus standard therapy for mild/normal COVID-19 | Intervention study | 21/2/2020 | Phosphoric chloroquine: two tablets phosphoric chloroquine bid | 2 tablets placebo BID | Canceled by the investigator | From 2020-02-20 To 2021-03-20 |
| 10 | ChiCTR2000030054 (Retrospective registration) |
An open randomized controlled trial for Chloroquine phosphate and Hydroxychloroquine sulfate in the treatment of mild and common novel COVID-19 | Intervention study | 22/2/2020 | Hydroxychloroquine sulfate gloup: Hydroxychloroquine sulfate 0.2g bid for 14 days Chloroquine phosphate gloup: The first dose of chloroquine phosphate was 1 g for 2 days, and the 3rd day was 0.5 g for 12 days |
Recommended treatment plan for novel coronavirus pneumonia diagnosis and treatment plan | Not yet recruiting. | From 2020-02-22 To 2020-05-21 The time of sharing IPD will be within 6 months after the trial complete. |
| 11 | ChiCTR2000030417 | Efficacy and safety of chloroquine phosphate inhalation combined with standard therapy in the treatment of novel COVID-19 | Intervention study | 01/3/2020 | Combined standard therapy of chloroquine phosphate aerosol inhalation solution | Water for injection atomization inhalation combined with standard therapy | Canceled by the investigator | From 2020-03-01 To 2020-06-30 |
| 12 | ChiCTR2000030718 (Retrospective registration) |
Randomized controlled trial for Chloroquine Phosphate in the Treatment of novel COVID-19 | Intervention study | 11/3/2020 | Chloroquine phosphate | Conventional therapy | Recruiting | From 2020-02-12 To 2020-05-30 The time of sharing IPD Real time access |
| 13 | ChiCTR2000030987 | Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of novel COVID-19 | Intervention study | 20/3/2020 | Experimental group 1: the oral trial drug favipiravir tablets plus chloroquine phosphatetablets tablets group Experimental group 2: the oral trial drug favipiravir tablet |
Placebo group | Recruiting | From 2020-03-05 To 2020-06-25 The time of sharing IPD will be within 6 months after the trial complete. |
| 14 | ChiCTR2000031204 (Retrospective registration) |
A multicenter, single-blind, randomized controlled clinical trial for chloroquine phosphate in the treatment of novel COVID-19 | Intervention study | 24/3/2020 | Chloroquine phosphate tablets via oral | Placebo | Recruiting | From 2020-01-30 To 2020-04-30 The time of sharing IPD will be within 6 months after the trial complete. |
bid, bis in die; IPD, information of participant data.